TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo January 25, 2024 Linda Rubinstein Chief Financial Officer Adverum Biotechnologies, Inc. 100 Cardinal Way Redwood City , CA Re: Adverum Biotechnologies, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed March 30, 2023 File No. 001-36579 Dear Linda Rubinstein: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences